Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23771Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsoumani, M. E. | en |
| dc.contributor.author | Kalantzi, K. I. | en |
| dc.contributor.author | Dimitriou, A. A. | en |
| dc.contributor.author | Ntalas, I. V. | en |
| dc.contributor.author | Goudevenos, I. A. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.date.accessioned | 2015-11-24T19:35:55Z | - |
| dc.date.available | 2015-11-24T19:35:55Z | - |
| dc.identifier.issn | 1940-1574 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23771 | - |
| dc.rights | Default Licence | - |
| dc.title | Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1177/0003319711427697 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/22144668 | - |
| heal.identifier.secondary | http://ang.sagepub.com/content/early/2011/12/14/0003319711427697.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2011 | - |
| heal.abstract | The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplatelet effectiveness of long-term administration of the original CHS with a generic clopidogrel besylate (CB) salt formulation in 86 patients with a history of an ACS. At 1 month after the episode, patients receiving 75 mg/d CHS were randomized to continue with CHS (n = 41) or to switch to 75 mg/d CB (n = 45). Platelet aggregation, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression, and platelet-leucocyte conjugates were determined before randomization and at 6 months afterward. No difference in any platelet parameter studied was observed between the 2 groups either before randomization or after 6 months of treatment with CHS or CB. We conclude that there is no difference in the antiplatelet efficacy between CB and CHS during long-term administration in patients with a history of an ACS. | en |
| heal.journalName | Angiology | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tsoumani-2011-Antiplatelet Efficac.pdf | 358.95 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
